Tvardi Therapeutics

Tvardi Therapeutics is a Houston-based biotechnology startup founded in 2017 with a focus on developing innovative medicines for cancer, chronic inflammatory diseases, and fibrotic conditions. Led by a team of experienced entrepreneurs, scientists, and physicians, the company is making significant strides in the field of medical research. At Tvardi Therapeutics, the primary focus is on the development of STAT3 inhibitors, crucial in controlling gene networks integral to the survival of cancer cells and the pathogenesis of inflammatory and fibrotic conditions. The company's lead compound, TTI-101, is currently undergoing a Phase Ia dose-escalating study to assess safety and dosing for subsequent studies. The recent Series B investment of $72.42M in June 15, 2021, from a consortium of prominent investors including ArrowMark Partners, Catalytic Impact Foundation, Piedmont Capital Investments, Sporos Bioventures, 683 CAPITAL, and Slate Path Capital, underscores the confidence in Tvardi's groundbreaking approach and potential for societal and economic impact. Tvardi Therapeutics' commitment to developing safe and effective STAT3 inhibitors has the potential to address unmet needs across a spectrum of diseases, positioning the company as a significant player in the biotechnology, healthcare, and pharmaceutical sectors.